Lumos Diagnostics Holdings Ltd
ASX:LDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lumos Diagnostics Holdings Ltd
Net Income (Common)
Lumos Diagnostics Holdings Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lumos Diagnostics Holdings Ltd
ASX:LDX
|
Net Income (Common)
-$7.2m
|
CAGR 3-Years
46%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Nanosonics Ltd
ASX:NAN
|
Net Income (Common)
AU$20.6m
|
CAGR 3-Years
26%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Polynovo Ltd
ASX:PNV
|
Net Income (Common)
AU$9.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SDI Ltd
ASX:SDI
|
Net Income (Common)
AU$11.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
17%
|
CAGR 10-Years
6%
|
|
|
Anteris Technologies Ltd
ASX:AVR
|
Net Income (Common)
-AU$94m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
Ansell Ltd
ASX:ANN
|
Net Income (Common)
$135.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-2%
|
|
Lumos Diagnostics Holdings Ltd
Glance View
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.
See Also
What is Lumos Diagnostics Holdings Ltd's Net Income (Common)?
Net Income (Common)
-7.2m
USD
Based on the financial report for Jun 30, 2025, Lumos Diagnostics Holdings Ltd's Net Income (Common) amounts to -7.2m USD.
What is Lumos Diagnostics Holdings Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
5%
Over the last year, the Net Income (Common) growth was 16%. The average annual Net Income (Common) growth rates for Lumos Diagnostics Holdings Ltd have been 46% over the past three years , 5% over the past five years .
